Akoya Biosciences as an Authorized Reseller
Visiopharm Announces Akoya Biosciences as an Authorized Reseller of Oncotopix® Discovery and Biotopix™
Visiopharm A/S announced today a partnership with Akoya Biosciences, the technology leader in multiplexed immunofluorescence including the Phenoptics™ portfolio with the Vectra® and Vectra Polaris® systems. As part of this agreement, Akoya becomes an authorized reseller of Visiopharm’s suite of image analysis software, including Phenomap™ and the teach-by-example Artificial Intelligence (AI) modules.
“Visiopharm is very pleased to have Akoya Biosciences join our partner and authorized reseller community. Our complementary technologies enable scientists and pathologists to better interrogate the disease biology through biomarker discovery and automated cell phenotyping within tissue samples. Our joint customers will benefit from two companies who are committed to driving innovation and providing solutions that deliver efficiency, standardization, and the reproducibility required to support large scale translational studies from discovery through clinical research” said Amanda Lowe, Senior Vice President of Visiopharm.
Akoya recently announced the acquisition of the Phenoptics portfolio from PerkinElmer, Inc., to complement the CODEX® platform for ultra-high multiplex capabilities. The enables analysis of multiplexed image data from the Mantra®, Vectra and Vectra Polaris platforms with future development for the CODEX technology.
“Akoya’s focus is to provide customers with end-to-end solutions for high parameter tissue analysis that includes multispectral imaging instruments, reagents, and powerful software.” said Terry Lo, President at Akoya Biosciences. “We are excited to be able to add software like Visiopharm’s Phenomap to our current portfolio and offer Akoya customers the best and broadest solutions in the field of multiplexed immunofluorescence and tissue analysis.”
The partnership with Akoya will cover both North America and Europe and support our joint vision of providing customers with a full suite of powerful image analysis solutions for high-dimensional, multiplex tissue assays.
Visiopharm will present Phenomap, AI, and our infinitely configurable suite of image analysis software at Pathology Vision’s (booth #214) in San Diego on November 5th and 6th and at Society of Immunotherapy in Cancer (booth #223) on November 8th – 11th in Washington DC.
Share this article
About Visiopharm
Visiopharm is a world leader in Augmented Pathology™ solutions. Leading biopharmaceutical companies, contract research organizations (CRO), academic medical centers, and hospital diagnostic pathology labs all over the world utilize our software platform for tissue-based research and diagnostics. Visiopharm provides scientists and pathologist with a scalable software solution that fits the needs and volumes of both research and diagnostic labs. Over the past 16 years Visiopharm has grown into an international business with over 800 installations and countless more users. Visiopharm software is featured in over 1350 scientific publications since 2010 and is compatible with leading slide scanning systems and data management software. A growing network of authorized distributors and integration partners support the growth of Visiopharm solutions on several continents including North America, Europe and Asia. Our headquarters is in the Medicon Valley of Denmark, with a branch office in the United Kingdom, and a North American office in Broomfield, Colorado.
For more information, please visit visiopharm.com.
About Akoya Biosciences
Akoya Biosciences develops innovative technologies for life science researchers to enable spatially-resolved, quantitative tissue phenotyping at the cellular and subcellular level. The combined technologies of Phenoptics and CODEX are fueling advances in next generation tissue analysis by providing comprehensive solutions including instrumentation, reagents and software. Akoya Biosciences is headquartered in Menlo Park, CA.
For more information, please visit akoyabio.com.
